Crinetics Pharmaceuticals, INC 8-K filings

Crinetics Pharmaceuticals announces the expiration of the HSR Act waiting period for its acquisition by Vertex Pharmaceuticals, moving closer to deal closure.

Crinetics Pharmaceuticals announced a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion, alongside reporting strong second-quarter 2026 financial results driven by PALSONIFY sales.

Crinetics Pharmaceuticals announces a definitive merger agreement with Vertex Pharmaceuticals, including non-compete agreements with key employees.

Vertex Pharmaceuticals announced its definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash, aiming to bolster its pipeline with endocrinology assets.

Crinetics Pharmaceuticals announced first-quarter 2026 financial results, highlighting $10.3 million in net product revenue for PALSONIFY and providing business updates on clinical trials and regulatory approvals.

Crinetics Pharmaceuticals announces the departure of Jeff Knight as Chief Development and Operating Officer, transitioning to an independent consultant role.

Crinetics Pharmaceuticals announces the resignation of Chief Development and Operating Officer Jeff Knight, effective April 10, 2026, citing no disagreement with company operations.

Crinetics Pharmaceuticals announced strong Q4 2025 PALSONIFY revenue and positive clinical trial advancements, alongside increased operating expenses and net loss.

Crinetics Pharmaceuticals announced a title change for Jeff Knight from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, 2026, reflecting expanded responsibilities.

Crinetics Pharmaceuticals announced preliminary Q4 2025 net product revenue exceeding $5.0 million for PALSONIFY and provided updates on its late-stage clinical pipeline.

Crinetics Pharmaceuticals announced the pricing of an underwritten public offering of 7.62 million shares of common stock at $45.95 per share, aiming to raise approximately $330.2 million in net proceeds.

Crinetics Pharmaceuticals announced preliminary Q4 2025 PALSONIFY revenue exceeding $5 million and positive Phase 2 results for atumelnant in congenital adrenal hyperplasia.

Crinetics Pharmaceuticals announces Chief Medical and Development Officer Dana Pizzuti will transition to a strategic advisory role, ensuring continuity for key regulatory initiatives.

Crinetics Pharmaceuticals reported strong initial uptake for its newly approved drug PALSONIFY, alongside significant pipeline advancements and a reiterated cash runway into 2029, despite increased operating expenses and net loss.

Crinetics Pharmaceuticals announced FDA approval for PALSONIFY (paltusotine), the first once-daily, oral treatment for adults with acromegaly.

Crinetics Pharmaceuticals reported second quarter 2025 financial results, highlighting progress on PALSONIFY's FDA review with a September 25, 2025 PDUFA date and a strong cash position extending into 2029.

Crinetics Pharmaceuticals announced it will present eight abstracts, including long-term efficacy and safety data for PALSONIFY and Phase 2 results for atumelnant, at the upcoming Endocrine Society's Annual Meeting, ENDO 2025.

Crinetics Pharmaceuticals, Inc. presented positive preclinical data for its early-stage pipeline assets, CRN12755 for Graves disease, CRN10329 for ADPKD, and CRN09682 for SST2+ tumors, outlining strategic next steps and clinical development plans.

Crinetics Pharmaceuticals, Inc. announced that its stockholders approved the election of three Class I directors, ratified BDO USA, P.C. as its independent accounting firm, and approved executive compensation on an advisory basis at its annual meeting held on June 11, 2025.

Crinetics Pharmaceuticals reports Q1 2025 financial results, highlighting progress with paltusotine's regulatory review and the advancement of its clinical programs.

Crinetics Pharmaceuticals has engaged its former CFO, Marc Wilson, as an independent consultant to provide accounting and finance services for a one-year period.

Crinetics Pharmaceuticals announces its fourth quarter and full year 2024 financial results, highlighting commercial preparation progress, upcoming late-stage trials, and a strong financial position.

Crinetics Pharmaceuticals announces the appointment of Tobin Schilke as its new Chief Financial Officer, effective February 28, 2025, replacing Marc Wilson.

Crinetics Pharmaceuticals provides a corporate update, highlighting key priorities for 2025, including commercial readiness for paltusotine and continued development of atumelnant.

Crinetics Pharmaceuticals reports successful topline results from its Phase 2 trial of atumelnant, showing significant reductions in key biomarkers and improvements in clinical signs and symptoms for patients with congenital adrenal hyperplasia (CAH).

Crinetics Pharmaceuticals has appointed Isabel Kalofonos as Chief Commercial Officer to lead the commercial strategy for the potential launch of paltusotine and other pipeline candidates.

The FDA has accepted Crinetics Pharmaceuticals' New Drug Application for paltusotine, a potential new treatment for acromegaly.

Crinetics Pharmaceuticals announced the submission of a New Drug Application for paltusotine, a $575 million public offering, and advancements in their drug pipeline.

Crinetics Pharmaceuticals has entered into a consulting agreement with former COO James Hassard following his departure, effective October 14, 2024.

Crinetics Pharmaceuticals has announced the pricing of an upsized public offering of 10,000,000 shares of its common stock at $50.00 per share, with an option for underwriters to purchase an additional 1,500,000 shares.